BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage ophthalmology programs and establish...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

...Venture, KTB Network, Hontai Capital, CDIB, Trinity, Elements Capital...
BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...
BioCentury | Sep 7, 2018
Financial News

Fourth Element Capital raising first $175M fund

Fourth Element Capital (Minneapolis, Minn.), founded by Kathleen Tune and John Deedrick, is raising a $175 million debut fund to invest in companies within the medtech, device, tool, diagnostic and specialty pharma space. Deedrick told...
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd. (Cambridge, U.K.). The newco will seek to discover and develop small molecule...
BioCentury | Sep 22, 2017
Financial News

XW Labs raises $17.5M in series B

...Inc. (Wuhan, China) said it raised $17.5 million in a series B round led by Elements Capital...
BioCentury | Sep 20, 2017
Financial News

XW Labs raises $17.5M series B

...Inc. (Wuhan, China) said it raised $17.5 million in a series B round led by Elements Capital...
BioCentury | Jan 6, 2017
Financial News

Synthego completes venture financing

...$41 million in a series B round led by 8VC. New investors AME Cloud Ventures, Elements Capital...
Items per page:
1 - 10 of 14
BioCentury | Mar 11, 2021
Deals

March 10 Quick Takes: Eddy Wu’s Arctic Vision raises $100M; plus Touchlight, NeoPhore, MediciNova-BARDA and Neurelis

Arctic Vision (Shanghai) Biotechnology Co. Ltd. raised $100 million in a series B round led by Loyal Valley Capital. The funds will go in part to support the company’s trio of late-stage ophthalmology programs and establish...
BioCentury | Sep 25, 2020
Emerging Company Profile

XWPharma: timing therapy to biological rhythm

...Venture, KTB Network, Hontai Capital, CDIB, Trinity, Elements Capital...
BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

Syncona is taking a majority stake in University of Cambridge spinout Azeria by leading the company's £32 million ($41.5 million) series B round, with which the start-up hopes to bring its first FOXA1 inhibitor into...
BioCentury | Aug 1, 2019
Emerging Company Profile

NeoPhore: Driving neoantigen production via DNA mismatch repair

NeoPhore is turning cold tumors hot by inhibiting DNA mismatch repair to produce more of the neoantigens that trigger immune attack. Immuno-oncology companies are developing therapies based on neoantigens -- tumor-specific peptides that the immune...
BioCentury | Sep 7, 2018
Financial News

Fourth Element Capital raising first $175M fund

Fourth Element Capital (Minneapolis, Minn.), founded by Kathleen Tune and John Deedrick, is raising a $175 million debut fund to invest in companies within the medtech, device, tool, diagnostic and specialty pharma space. Deedrick told...
BioCentury | Nov 17, 2017
Company News

Sixth Element, PhoreMost spin out immuno-oncology newco

Sixth Element Capital LLC invested £3 million ($4 million) in newly created NeoPhore Ltd. (Cambridge, U.K.), a spinout from cancer company PhoreMost Ltd. (Cambridge, U.K.). The newco will seek to discover and develop small molecule...
BioCentury | Sep 22, 2017
Financial News

XW Labs raises $17.5M in series B

...Inc. (Wuhan, China) said it raised $17.5 million in a series B round led by Elements Capital...
BioCentury | Sep 20, 2017
Financial News

XW Labs raises $17.5M series B

...Inc. (Wuhan, China) said it raised $17.5 million in a series B round led by Elements Capital...
BioCentury | Jan 6, 2017
Financial News

Synthego completes venture financing

...$41 million in a series B round led by 8VC. New investors AME Cloud Ventures, Elements Capital...
Items per page:
1 - 10 of 14